Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
DAR1 Drug Antibody Ratio 1:1
DAR4 Drug Antibody Ratio 4:1
DAR2 Drug Antibody Ratio 2:1
toxSYN® Linker-Payload
Mode-of-Action
Payload (Active Catabolite)
1. SYNtecan E™*
Topoisomerase 1 inhibitor
Camptothecin-based
2. SYNeamicin D™*
DNA damaging agent
Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*
Nemorubicin-based
5. SYNstatin E™
Microtubule inhibitors
Auristatin-based
6. SYNstatin F™
7. SYNtansine™
Maytansine-based
* Patent protection filed by Synaffix, beyond the claims of GlycoConnect® and HydraSpace®